Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12679303 | 0.90 | TACR1 (0.47) | TACR1TACR3 | |
| SCHEMBL24384391 | 0.83 | TACR1 (0.56) | TACR1TACR3 | |
| SCHEMBL19773685 | 0.83 | TACR1 (0.56) | TACR1TACR3 | |
| SCHEMBL14291284 | 0.81 | TACR1 (0.55) | TACR1TACR3 | |
| SCHEMBL14409525 | 0.79 | TACR1 (0.52) | TACR1TACR3 | |
| SCHEMBL6299556 | 0.78 | TACR1 (0.50) | TACR1TACR3 | |
| SCHEMBL6299562 | 0.78 | TACR1 (0.50) | TACR1TACR3 | |
| SCHEMBL14291052 | 0.77 | TACR1 (0.51) | TACR1TACR3 | |
| SCHEMBL12451725 | 0.76 | TACR1 (0.49) | TACR1TACR3 | |
| SCHEMBL12203906 | 0.76 | TACR1 (0.49) | TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822116-B2 | Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds | OPKO HEALTH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170283434-A1 | NK1 ANTAGONISTS | OPKO HEALTH INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-9688693-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160145256-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS | TERSERA THERAPEUTICS LLC | 2016-05-26 | — | — | US | disclosed |
| US-9249144-B2 | Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds | OPKO HEALTH, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140336158-A1 | NK1 ANTAGONISTS | TERSERA THERAPEUTICS LLC | 2014-11-13 | — | — | US | disclosed |
| US-8796299-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140031549-A1 | Process and Intermediates for the Synthesis of 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one Compounds | OPKO HEALTH, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130023503-A1 | NK1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8273895-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110098468-A1 | NK1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7902366-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902366-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1451153-B1 | NK1 ANTAGONISTS | SCHERING CORP (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7122677-B2 | NK1 antagonists | SCHERIG CORPORATION (US) | 2006-10-17 | — | — | US | disclosed |
| US-20030144270-A1 | NK1 antagonists | SCHERING CORPORATION | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283434-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | TACR1 22/4885TACR3 304/4885 |
| US-20110098468-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | TACR1 22/4885TACR3 304/4885 |
| US-20140336158-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | TACR1 22/4885TACR3 304/4885 |
| US-20130023503-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | TACR1 22/4885TACR3 304/4885 |
| US-20140031549-A1 | Process and Intermediates for the Synthesis of 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one Compounds | SKP1, PBK, KCNJ8 | TACR1 332/4885TACR3 928/4885 |
| US-20030144270-A1 | NK1 antagonists | BDKRB2, PROKR1, CRH | TACR1 10/4885TACR3 201/4885 |
| US-20160145256-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS | SKP1, PBK, KCNJ8 | TACR1 332/4885TACR3 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.